Interview with Sandeep Gupta, Chairman and Managing Director, Eli Lilly and…
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of the Indian market. How…
Address: Genome Valley ShameerpetHyderabad – 500 078 AP India
Tel: +91 40 2348 0567
Web: http://www.bharatbiotech.com/
(BBIL/Bharat Biotech), Hyderabad, India, is a multidimensional biotechnology company specialising in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech, established in the year 1996 by Dr. Krishna M. Ella & Mrs. Suchitra K. Ella as the Founder Directors, is engaged in developing next-generation vaccines and bio-therapeutics through innovative and collaborative research.
BBIL’s state-of-the-art manufacturing plant is the largest of its kind in Asia-Pacific. The first bio-pharma facility in the country to be audited and approved by Korean Food & Drugs Administration (KFDA), it sprawls over a picturesque campus at Genome Valley, Hyderabad. Built with an investment of over INR 1000 million, the facility’s Manufacturing, Control Procedures and Protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO.
Bharat Biotech has set new benchmarks in Innovation and Quality that epitomizes the tremendous progress of Indian biotechnology in the global arena.
Our business strategy is to research, develop, manufacture and market products that have a broad market scope. It also means of achieving Pioneering research. Healthy tomorrow. We build value by the skilled management of pre-clinical and clinical development, steering the process efficiently to the completion of clinical studies that demonstrate safety and efficacy.
-IMMUTIKA Vaccine Division
-RENOVA Bio-therapeutics Division
-PrefeRx Women Health Care Division
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of the Indian market. How…
Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had…
When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these…
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take many shapes and forms and that different companies in India will keep…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
The managing director of Encube Ethicals discusses contract manufacturing in India today, growing competition from China, and partnering with the world’s leading multinational pharma companies. Mr Dilip Shah from…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
See our Cookie Privacy Policy Here
